Z3 Capital Partners’s abrdn Life Sciences Investors HQL Stock Holding History

Z3 Capital Partners’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.44M	Buy	72,030 +4,681	+7%	+$82.7K	0.3%	62
2026 Q1	$1.1M	Buy	67,349 +500	+0.7%	+$8.36K	0.28%	71
2025 Q4	$1.12M	Buy	+66,849	New	+$1.12M	0.27%	68

Other funds holding HQL

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

Z3 Capital Partners's HQL Position: Q2 2026 in Review

Z3 Capital Partners increased its abrdn Life Sciences Investors (HQL) stake by 7% in Q2 2026, buying an estimated $82.7K and bringing the position to 72,030 shares worth $1.44M. The position accounts for 0.3% of the portfolio, ranked #62.

Z3 Capital Partners first reported a position in HQL in Q4 2025 and has held it in 3 quarters since. 77 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

Z3 Capital Partners held 72,030 shares of abrdn Life Sciences Investors worth $1.44M as of Q2 2026.
Z3 Capital Partners bought 4,681 abrdn Life Sciences Investors shares in Q2 2026, an estimated $82.7K.
abrdn Life Sciences Investors made up 0.3% of Z3 Capital Partners's portfolio in Q2 2026, its #62 holding.
Z3 Capital Partners first reported a position in abrdn Life Sciences Investors in Q4 2025 and has held it in 3 quarters since.
77 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Z3 Capital Partners's 13F filing for Q2 2026, filed 28 Jul 2026.